butanediol monomethacrylate | 29721-79-7

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: butanediol monomethacrylate
• 英文别名: hydroxybutyl methacrylate；butanediol di(meth)acrylate；1-Hydroxybutyl 2-methylprop-2-enoate
• CAS: 29721-79-7
• 化学式: C₈H₁₄O₃
• 分子量: 158.197
• InChiKey: QNMHRRCVEGQTPS-UHFFFAOYSA-N

物化性质

• 沸点：
  222.85-223.85℃ at 101.38kPa
• 密度：
  1.01 at 20℃
• LogP：
  0.772 at 30℃
• 表面张力：
  57-57.1mN/m at 1.01-1.02g/L and 21.6-21.8℃

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  11
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  1,2-环氧丁烷 、 甲基丙烯酸 、 三甲基苯甲氧基胺 在 sodium hydroxide 作用下， 以 甲醇 、 乙酸乙酯 为溶剂， 生成 butanediol monomethacrylate
  参考文献：
  名称：

  Monomeric compounds

  摘要：

  含有重复单元的光敏同聚物和基本非交联的共聚物，其中：##EQU1## R.sub.1可以是取代或未取代的烷基，芳基烷基，烷氧基烷基或芳氧基烷基。 R.sub.2是具有芳香性质的取代或未取代的芳基或杂环基。 R.sub.3、R.sub.4和R.sub.5是氢、卤素或较低烷基。 R.sub.6和R.sub.7可以是氢、卤素、硝基、较低烷基、苯基、取代苯基、苯氧基和较低烷氧基。 负载这些光敏聚合物的平版可以在曝光之前存放很长时间而不会发生恶化，并在曝光后产生高度耐磨的平版。 该发明的光敏聚合物首选通过使用具有下述一般式的新单体的同聚合制备：##EQU2## 其中R.sub.1 .sub.'是烷基，卤代烷基，烷氧基烷基，氨基烷基，环烷基，芳基烷基，环烷烷基，氰基烷基和芳氧基烷基，R.sub.2、R.sub.3、R.sub.4、R.sub.5、R.sub.6和R.sub.7如上所定义；以及通过这些单体与一个或多个乙烯基不饱和共聚物单体的共聚制备。 还披露了制备光聚合物和新单体的方法，以及制备和曝光负载聚合物的平版的方法。

  公开号：

  US03993684A1

文献信息

• METHODS FOR PRODUCING BIOCOMPATIBLE MATERIALS
  申请人：Driver Michael

  公开号：US20130059926A1

  公开（公告）日：2013-03-07

  A method for producing polymerisable solution which comprises dissolving an ethylenically unsaturated zwitterionic monomer in a co-monomer system comprising a functionalised ethylenically unsaturated monomer in which the zwitterionic monomer is soluble, a siloxane group-containing monomer or macromer, and a crosslinking agent is disclosed. The polymerisable solution is biocompatible and can be used to produce polymers and articles such as contact lenses.

  一种生产可聚合溶液的方法，该方法包括将一种乙烯基不饱和的两性离子单体溶解在共单体系统中，该共单体系统包括一种功能性乙烯基不饱和单体，在该单体中两性离子单体是可溶的，一种含有硅氧烷基团的单体或大单体，以及一种交联剂。所述的可聚合溶液具有生物相容性，可用于生产聚合物和制品，如隐形眼镜。
• ENGINEERED CELLS AND AGENT COMPOSITIONS FOR THERAPEUTIC AGENT DELIVERY AND TREATMENTS USING SAME
  申请人：UNIVERSITY OF WASHINGTON

  公开号：US20200276318A1

  公开（公告）日：2020-09-03

  Provided herein are engineered cells and methods for engineering cells to deliver a therapeutic agent, e.g., a small molecule, peptide or other drug, to a cell or tissue to be treated.

  本文提供了经过工程改造的细胞以及用于工程改造细胞以传递治疗剂的方法，例如小分子、肽或其他药物，以传递到待治疗的细胞或组织。
• [EN] FORCE-RESPONSIVE POLYMERSOMES AND NANOREACTORS; PROCESSES UTILIZING THE SAME<br/>[FR] POLYMERSOMES ET NANORÉACTEURS SENSIBLES À LA FORCE; PROCÉDÉS LES UTILISANT
  申请人：ADOLPHE MERKLE INSTITUTE UNIV OF FRIBOURG

  公开号：WO2019034597A1

  公开（公告）日：2019-02-21

  The mechanically induced melting properties of DNA were employed to achieve force labile membranes is described. Nucleobase pairs were used as mechanophores. Adenine and thymine functionalized complementary amphiphilic block copolymers were self-assembled into polymersomes. The nucleobases formed hydrogen bonds which were disrupted upon force stimulation. The exposure of the disconnected nucleobases to the hydrophobic matrix of the membranes lead to a change of permeability which permitted the exchange of water-soluble molecules throughout the polymer matrix. Moreover, the encapsulation of horseradish peroxidase enabled the reaction of luminol with hydrogen peroxide to yield a luminescence producing species similar to the marine bioluminescence. Moreover, the same nano-reactors were employed to catalyze the formation of a polyacrylamide gel when force was applied. Insights into the change of permeability of supramolecular networks upon force are provided. These systems are useful for drug delivery, as nanoreactors and for the selective release of curing agents for 3D printing, or fragrances.

  DNA的机械诱导熔化特性被用来实现易受力破裂的膜。核碱基对被用作机械感受器。腺嘌呤和胸腺嘧啶功能化的互补两性分块共聚物自组装成聚合体囊。核碱基形成氢键，在受力刺激下被破坏。断开的核碱基暴露在膜的疏水基质中，导致渗透性的改变，从而允许水溶性分子在聚合物基质中交换。此外，封装辣根过氧化物酶使得辣根酰胺与过氧化氢反应产生类似海洋生物发光的发光物种。此外，当施加力时，相同的纳米反应器被用来催化聚丙烯酰胺凝胶的形成。提供了关于受力下超分子网络渗透性变化的见解。这些系统可用于药物传递、纳米反应器以及用于3D打印的固化剂或香料的选择性释放。
• Multivalent indole compounds and use thereof as phospholipase-A2 inhibitors
  申请人：Chang Han-Ting

  公开号：US20070135385A1

  公开（公告）日：2007-06-14

  Indole and indole-related compounds, compositions and methods are disclosed. The compounds of the invention are useful as phospholipase inhibitors. The compounds and compositions of the invention are useful for treatment of phospholipase-related conditions, such as insulin-related, weight-related and/or cholesterol-related conditions in an animal subject.

  吲哚和与吲哚相关的化合物、组合物以及方法被披露。发明中的这些化合物作为磷脂酶抑制剂非常有用。发明中的这些化合物和组合物用于治疗动物受试者中的磷脂酶相关状况，例如胰岛素相关、体重相关和/或胆固醇相关状况。
• [EN] INHIBITORS OF NHE-MEDIATED ANTIPORT<br/>[FR] INHIBITEURS D'ANTIPORT À MÉDIATION PAR NHE
  申请人：ARDELYX INC

  公开号：WO2018129557A1

  公开（公告）日：2018-07-12

  The present disclosure is directed to compounds (Ι') and to their use in methods for the treatment of disorders associated with fluid retention or salt overload, such as heart failure (in particular, congestive heart failure), chronic kidney disease, end-stage renal disease, liver disease, and peroxisome proliferator-activated receptor (PPAR) gamma agonist-induced fluid retention. The present disclosure is also directed to compounds (Ι') and their use in methods for the treatment of hypertension. The present disclosure is also directed to compounds (Ι') and to their use in methods for the treatment of gastrointestinal tract disorders, including the treatment or reduction of pain associated with gastrointestinal tract disorders.

  本公开涉及化合物(Ι')及其在治疗与液体潴留或盐超负荷相关的疾病的方法中的用途，例如心力衰竭（尤其是充血性心力衰竭）、慢性肾病、终末期肾病、肝病以及过氧化物酶体增殖物激活受体（PPAR）gamma激动剂引起的液体潴留。本公开还涉及化合物(Ι')及其在治疗高血压的方法中的用途。本公开还涉及化合物(Ι')及其在治疗胃肠道疾病的方法中的用途，包括治疗或减少与胃肠道疾病相关的疼痛。